ACCURAY WKN: A0MKWM ISIN: US0043971052 Kürzel: XEJ Forum: Aktien Thema: Hauptdiskussion

Accuray Reports Fourth Quarter and Fiscal 2022 Financial Results https://www.prnewswire.com/news-releases/accuray-reports-fourth-quarter-and-fiscal-2022-financial-results-301603116.html 8.5% FY22 revenue growth; Company issues guidance for FY23

https://www.surgicalroboticstechnology.com/news/new-clinical-studies-show-benefits-of-accuray-cyberknife-in-treatment-of-neurological-indications/

Sau 👍

Accuray CyberKnife® System Real World Data and Clinical Studies Show Benefits in Treatment of Neurological https://www.prnewswire.com/news-releases/accuray-cyberknife-system-real-world-data-and-clinical-studies-show-benefits-in-treatment-of-neurological-indications-301583528.html

https://www.benzinga.com/quote/ARAY/analyst-ratings Accuray Price Target Announced at $7.50/Share by B. Riley Securities

Accuray and Limbus AI Inc. Partner to Leverage Limbus' Innovative AI-driven Technology to Enhance Accuray Adaptive Radiotherapy Solutions https://www.prnewswire.com/news-releases/accuray-and-limbus-ai-inc-partner-to-leverage-limbus-innovative-ai-driven-technology-to-enhance-accuray-adaptive-radiotherapy-solutions-301559886.html Partnership will Enable Accuray to Use Limbus' Technology to Streamline the Treatment Planning Process and Increase Operational Efficiency

New Data Presented at ESTRO 2022 Reinforce Benefits of Accuray CyberKnife® and TomoTherapy® Platforms Across a Range of Indications and Complexities https://www.prnewswire.com/news-releases/new-data-presented-at-estro-2022-reinforce-benefits-of-accuray-cyberknife-and-tomotherapy-platforms-across-a-range-of-indications-and-complexities-301543379.html More Than 70 Abstracts Build on the Clinical Evidence Supporting the Use of These Technologies

Accuray ClearRT™ Helical Fan-Beam kVCT Imaging Wins "Best New Technology Solution for Oncology" MedTech Breakthrough Award https://www.prnewswire.com/news-releases/accuray-clearrt-helical-fan-beam-kvct-imaging-wins-best-new-technology-solution-for-oncology-medtech-breakthrough-award-301540539.html Annual Awards Program Recognizes Outstanding Health & Medical Technology Products and Companies

https://investors.accuray.com/news-releases/news-release-details/accuray-announces-suzanne-winter-president-promoted-president

Accuray Reports Fiscal 2022 Third Quarter Financial Results https://www.prnewswire.com/news-releases/accuray-reports-fiscal-2022-third-quarter-financial-results-301533954.html

https://www.prnewswire.com/news-releases/owner-of-arkansas-derby-winner-named-horse-after-the-life-changing-accuray-cyberknife-radiation-therapy-technology-used-to-treat-his-cancer-301529800.html

10-Year Data Shows Accuray CyberKnife® System Provides Long-Lasting Relief of the Excruciating Pain Caused by Trigeminal Neuralgia https://www.biospace.com/article/releases/10-year-data-shows-accuray-cyberknife-system-provides-long-lasting-relief-of-the-excruciating-pain-caused-by-trigeminal-neuralgia/

CARTI Selects Accuray CyberKnife® S7™ System to Increase Access to Advanced Cancer Care for Patients in Rural Communities Throughout Arkansas CARTI is First in Arkansas to Treat Patients with World's Only Robotic Radiosurgery System https://www.prnewswire.com/news-releases/carti-selects-accuray-cyberknife-s7-system-to-increase-access-to-advanced-cancer-care-for-patients-in-rural-communities-throughout-arkansas-301497478.html

https://www.prnewswire.com/news-releases/largest-hospital-in-queensland-australia-acquires-multiple-accuray-radixact-systems-with-the-clearrt-helical-fan-beam-kvct-imaging-and-synchrony-technologies-301481340.html

https://www.benzinga.com/node/25532597

Accuray GAAP EPS of $0.00 in-line, revenue of $116.28M beats by $13.35M https://seekingalpha.com/news/3792078-accuray-gaap-eps-of-0_00-in-line-revenue-of-116_28m-beats-13_35m FQ2 GAAP EPS of $0.00 in-line. Revenue of $116.28M (+19.3% Y/Y) beats by $13.35M. Gross orders of $85.4 million, an increase of 13 percent compared to the prior year. Revising guidance 2022: Total revenue is being increased to an expected range of $420.0 million to $430.0 million compared to the prior range of $420.0 million to $427.0 million, representing a year-over-year growth at the midpoint of the range of 7%. Adjusted EBITDA is now expected to range between $15.0 million to $20.0 million compared to the prior range of $33.0 million to $35.0 million.